WHO vaccine-preventable diseases: monitoring system. 2016 global summary

Last updated 15-July-2016 (15-July-2016)
Next overall update Fall 2016
EPI mother and child logo         
Select a country

Development status: Developed economy GNI / capita (US$): 61'3101 Infant (under 12 months) mortality rate: 32
GDP / capita (US$): 44'8631 Child (under 5 years) mortality rate: 42

Population data in thousands3

  2015  2014  2013  2012  2011  2000  1990  1980 
Total population 5'669  5'647  5'624  5'601  5'577  5'338  5'140  5'123 
Births 59  59  59  59  60  66  62  57 
Surviving infants 59  59  59  59  60  65  62  56 
Pop. less than 5 years 295  300  309  319  326  338  291  313 
Pop. less than 15 years 957  964  974  985  994  986  875  1'067 
Female 15-49 years 1'267  1'267  1'265  1'262  1'258  1'253  1'306  1'224 

Number of reported cases

(Click for retrospective incidence data for Denmark)
Diphtheria
ChartChart
 
Japanese encephalitis
ChartChart
 
Measles
ChartChart ChartChart
  27  17  84  14  180  28'249 
Mumps
ChartChart
  15  41  60  15  13  34 
Pertussis
ChartChart
  962  855  484  980  71  164  569  4'970 
Polio*
ChartChart
 
Rubella
ChartChart
 
Rubella (CRS)
ChartChart
 
Tetanus (neonatal)
ChartChart
 
Tetanus (total)**
ChartChart
 
Yellow fever
ChartChart
 
* Polio refers to all polio cases (indigenous or imported), including polio cases caused by vaccine derived polio viruses (VDPV). For desagregated data please click on this hyperlink: https://extranet.who.int/polis/public/CaseCount.aspx
it does not include cases of vaccine-associated paralytic polio (VAPP) and cases of non polio acute flaccid paralysis [AFP]).
** Neonatal Tetanus and Total Tetanus cases equality may be the result from a lack of non-Neonatal Tetanus surveillance system.

Percentage target population vaccinated by antigen

Hovering over an antigen reveals its fuller definition
  Most recent coverage survey4  

Official country estimates5

  (Click for retrospective coverage estimates data for Denmark)
Vaccine year result method % card seen                                                
BCG         
DTP1          96  96  97  97  94  95  98  97 
DTP3          93  94  94  94  91  97  90  88 
DTP4          83  86 
IPV1          96  96 
HepB_BD         
HepB3         
Hib3          93  94  94  94  91  95 
JapEnc         
MCV1          91  90  89  90  87  99*  84 
MCV2          80  84  86  87  86 
PCV1          92  94  95  95  92 
PCV3          91  93  94  93  90 
Pol3          93  94  94  94  91  97  99  99 
Rota1         
RotaC         
Rubella1          91  90  86  90  87 
TT2plus         
PAB         
VAD1         
YFV         
° indicates that more than 1 survey occurred that year.  * indicates the country reported above 100% coverage.

  Next update: Mid July 2017

WHO-UNICEF estimates6

  (Click for full retrospective WHO-UNICEF coverage estimates data for Denmark)
BCG
ChartChart
 
DTP1
ChartChart
  96  96  97  97  94  98  98  97 
DTP3
ChartChart
  93  94  94  94  91  97  90  88 
HepB3
ChartChart
 
HepB_BD
ChartChart
 
Hib3
ChartChart
  93  94  94  94  91  95 
MCV1
ChartChart
  91  90  89  90  87  99  84 
MCV2
ChartChart
  80  84  86  87  86 
PCV3
ChartChart
  91  93  90  93  90 
Pol3
ChartChart
  93  94  94  94  91  97  99  99 
RCV1
ChartChart
  91  90  89  90  87  99  84 
RotaC
ChartChart
 

Number of districts in the country 11  Proportion of
districts reporting
DTP3 coverage:
% of coverage reports received at national
level vs number of reports expected
100 
   
/
|
|
\
Greater or equal to 90% 64
From 80 to 89% 36
From 50 to 79% 0
Less than 50% 0
Proportion of districts
not reporting DTP3 coverage
0
DTP3 reported coverageDTP3 reported coverage

Immunization Schedule (2015 or latest available)

Hovering over an antigen reveals its fuller definition
Vaccine Schedule Entire country Comment
DTaPHibHepIPV 3, 5, 12 months; Yes temporarily in use in 2015
DTaPHibIPV 3, 5, 12 months; Yes
DTaPIPV 5 years; Yes
HPV 12 years; +6 months; Yes
HepB_Pediatric birth; 1, 2, 12 months; Yes Neonates of HBsAG pos mothers (if not administrated as part of the temporarly Hexavalent)
Influenza_Adult >= 65 years; Yes and pregnant women, adults with chronic diseases and other risk groups
Influenza_Pediatric Yes children with chronic diseases
MMR 15 months; 4 years; Yes (MMR2 at Y12 until 2016)
Pneumo_conj 3, 5, 12 months; Yes

Immunizaton indicators

Indicator Expected answer 2015  2014  2013  2012  2011  2010  2009 

Planning and management

Has the country a Multi-Year Plan (MYP) for immunization? Yes/No/NR Yes  Yes  Yes  Yes  Yes  Yes  Yes 
What years does the MYP cover? number              
Nº of districts with microplans that include activities to raise immunization coverage number              

System performance

Total Nº districts in country number 11  11  11  11  11  11 
Nº districts with DTP3 coverage >=80% number 11  11  11  11  11  11   
% of districts with DTP3 coverage >=80% From 0 to 100% 100  100  100  100  100  100   
Nº districts with measles (MCV1) coverage >=95% number    
% of districts with MCV1 coverage >=95% From 0 to 100%    

Safety

Has the country a vaccine adverse events review committee? Yes/No/NR/ND Yes  Yes  Yes  Yes  Yes  Yes   
Is there a national system to monitor adverse events following immunization (AEFI)? Yes/No/NR Yes  Yes  Yes  Yes  Yes  Yes  Yes 

Finance

Immunization expenditure financed, using Government funds? From 0 to 100%              

National Immunization Advisory Mechanism

Has the country a standing technical advisory group on immunization (NITAG)? Yes/No/NR Yes  Yes  Yes  Yes  Yes  Yes   

Sources

 1  "The 2013 World Bank Development Indicators Online", GDP per capita is PPP adjusted.
 2  World Health Statistics 2013, data for 2012
 3  "United Nations, Population Division. The World Population Prospects - the 2015 revision". New York, 2016.
 4  UNICEF/WHO survey database
 5  If no official estimate is available, the administrative coverage is reported. '*' indicates coverage over 99.5%.
 6  WHO-UNICEF estimates.